close

Agreements

1 2 3 4 257
Number of results: 5136

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2019-02-04 Cavogene LifeSciences (USA - OH) chief executive officer nomination Neurodegenerative diseases Nomination
2019-01-31 Janssen Pharmaceutical, a J&J Company (USA - NJ) Meira GtX (USA - NY) inherited retinal diseases including achromatopsia (ACHM) caused by mutations in either CNGB3 or CNGA3 and X-linked retinitis pigmentosa (XLRP) development - commercialisation Rare diseases - Genetic diseases - Ophtalmological diseases Development agreement
2019-01-31 Repare Therapeutics (Canada) Ono Pharmaceutical (Japan) Pol? inhibitor program R&D - research - development - commercialisation Cancer - Oncology Research agreement
2019-01-30 Aduro Biotech (USA - CA) restructuring Autoimmune diseases – Inflammatory diseases - Cancer - Oncology Restructuring
2019-01-28 Curevac (Germany) chief development officer nomination Cancer - Oncology - Infectious diseases Nomination
2019-01-25 MaSTherCell (Belgium), a Orgenesis' subsidiary (USA - NY) 30,000 sq. ft manufacturing facility in Houston construction of new premises Technology - Services Construction of new premises
2019-01-25 MaSTherCell (Belgium), a Orgenesis' subsidiary (USA - NY) president, CEO nomination Technology - Services Nomination
2019-01-24 Sobi - Swedish Orphan Biovitrum (Sweden) AstraZeneca (UK) Synagis® (palivizumab) and MEDI8897 prevention of serious lower respiratory tract infections (LRTI) caused by respiratory syncytial virus (RSV) licensing agreement Infectious diseases Licensing agreement
2019-01-24 Arena Pharmaceuticals (USA - CA) United Therapeutics (USA - MD) ralinepag pulmonary arterial hypertension licensing Rare diseases - Cardiovascular diseases Licensing agreement
2019-01-24 Agenus (USA - MA) Gilead Sciences (USA - CA)
  • up to five novel immuno-oncology therapies including AGEN1423, AGEN1223 and AGEN2373
development - commercialisation Cancer - Oncology Development agreement
2019-01-24 Merck KGaA (Germany) Vertex Pharmaceuticals (USA - MA) two DNA-dependent protein kinase (DNA-PK) inhibitors – M9831 (formerly known as VX984) and an additional pre-clinical compound six undisclosed specific genetic disease indications licensing Genetic diseases Licensing agreement
2019-01-24 Dicerna Pharmaceuticals (USA - MA) chairman, member of the board of directors nomination Rare diseases - Genetic diseases Nomination
2019-01-24 Intellia Therapeutics (USA - MA) member of the board of directors nomination Cancer - Oncology - Immunological diseases Nomination
2019-01-24 ArQule (USA - MA) Basilea Pharmaceutica (Switzerland) Roche (Switzerland) clinical research Clinical research agreement
2019-01-24 Emergent BioSolutions (USA - MD) president and CEO nomination Infectious diseases Nomination
2019-01-23 The Institute for Clinical and Economic Review (ICER) (uSA - MA) National Institute for Health and Care Excellence (NICE) (UK) Canadian Agency for Drugs and Technologies in Health (CADTH) (Canada) alternative assessment methods for the evaluation of potentially curative treatments collaboration Collaboration agreement
2019-01-23 B-MoGen Biotechnologies (USA - MN) CytoSen Therapeutics (USA) gene-modified Natural Killer Cell (NK) therapies research - development Cancer - Oncology Research agreement
2019-01-23 HTG Molecular Diagnostics (USA - AZ) member of the scientific advisory board nomination Cancer - Oncology - Diagnostic Nomination
2019-01-23 Actinium Pharmaceuticals (USA - NY) executive vie-president nomination Cancer - Oncology Nomination
2019-01-23 Rigel Pharmaceuticals (USA - CA) Grifols (Spain) fostamatinib chronic immune thrombocytopenia licensing - commercialisation Autoimmune diseases – Inflammatory diseases - Rheumatic diseases Licensing agreement